Opexa Therapeutics (OPXA), a Woodlands-based biotech company specializing in the development of an innovative immunotherapy using T-cells to treat multiple sclerosis, as of April 30, 2013 has enrolled 48 patients with Secondary Progressive Multiple Sclerosis in a Phase IIb clinical test of the imilecleucel-T, autologous T-Cell Immunotherapy known as Tcelna™.
http://bionews-tx.com/news/2013/05/15/opexa-therapeutics-reports-first-quarter-2013-financial-results/
No comments:
Post a Comment